Indefinite Delivery Contract 36E79721D0007
Award Date
2/15/21
Last Date to Order
2/14/26
Federal Agency
National Acquisition Center
Awardee
Astrazeneca Pharmaceuticals LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The key points are as follows:
This is an Indefinite Delivery Contract (IDC) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of acalabrutinib 100mg tablets, with a one-year base period and four one-year option periods, for a total ceiling value of $913,915,470.
The contract will procure the acalabrutinib tablets for use by the VA, Bureau of...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency's Medical Supply Chain program to Astrazeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The $5,360,046.82 ceiling value contract has a period of performance from November 16, 2016 to November 15, 2026 and includes no set-aside designations.
Under this IDC, Astrazeneca has been awarded multiple Firm Fixed Price delivery orders to provide a variety of "Other Medical"...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) for pharmaceutical and medical products. The prime contractor is AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $11,746,924,720 and runs from September 30, 2019 to September 30, 2025.
Under this IDV, AstraZeneca has been awarded multiple task orders to provide vaccines, therapeutics, and other...
The provided information describes a single-award Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer. The $5,687,207.30 contract establishes Teva as the national prime vendor for Levalbuterol HCL Solution, a critical respiratory medication, for the Department of Defense, Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service.
This commercial item contract has a...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) valued at $109,085,460 to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of approximately 3.9 million Albuterol HFA inhalers with dose counters annually over a five-year period, with an initial one-year base period and four one-year option periods.
The contracted products will be distributed...
This federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Astellas Pharma US, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The BPA was established against the VA's Federal Supply Schedule contract for drugs and pharmaceuticals, and has a ceiling value of $296,500 through October 2025.
The BPA is for the procurement of the oncology drugs XTANDI and XOSPATA. This supports the VA's...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract to Avkare, LLC, a for-profit limited liability company, to provide abiraterone tablets. This 1-year base contract with four 1-year option periods has a potential value of $70,208,375.13. The contract will supply the VA, Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS) with an uninterrupted source of abiraterone acetate 250mg tablets, with...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a $9,494,690.00 Indefinite Delivery Contract (IDC) to Cipla USA Inc., a foreign-owned, for-profit pharmaceutical company, to supply Ambrisentan tablets. The contract has a base period of one year from April 1, 2021 to March 31, 2022, with four one-year option periods.
Ambrisentan is a specialty drug that requires enrollment in the Ambrisentan Shared Risk Evaluation and Mitigation Strategy (REMS) program. As such, the...
This Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Astellas Pharma US, Inc., a foreign-owned pharmaceutical manufacturer, provides for the procurement of drugs and pharmaceuticals, including specialty oncology medications. The $3.5 billion contract, awarded in 2021 with a period of performance through 2026, was established under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) and is designated as a multiple award vehicle.
Under this FSS...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Golden State Medical Supply, Inc., a for-profit manufacturer and distributor of pharmaceuticals. The contract, valued at up to $2,337,840, is for the delivery of Albuterol SO4 tablets to the VA, Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS) over a one-year base period plus four one-year option periods. This IDC was...